AM23-ST-01-O: Optimizing Apheresis Collections to Enable Hematopoietic Stem Cell Gene Therapies (Enduring)
Oct 18, 2023 4:00pm ‐ Oct 18, 2023 5:00pm
Expiration Date: Dec 31, 2025
Identification: AM23-ST-01-O
Credits: None available.
Gene therapy can potentially treat or cure a wide range of disease entities and is being used mainly in clinical trials and certain cases as FDA-approved therapies. The starting material for these treatments is often collected via apheresis procedures where a relatively large number of hematopoietic progenitor cells (HPCs) are needed in a short period of time to undergo ex vivo manipulation to generate a therapeutic drug product. This session will provide a brief overview of gene therapy, using sickle cell disease, beta-thalassemia, and active cerebral adrenoleukodystrophy (CALD) as examples to illustrate strategies for gene editing/introduction. We will describe challenges with the mobilization and collection of HPCs and potential solutions for optimization of mobilization/collection of HPCs and discuss the risks and benefits of gene therapy as well as strategies to measure success.The audience for this session includes physicians, laboratory and quality personal involved in HPC mobilization and collection, apheresis centers, and blood banks that may be processing and shipping cells for manufacture.
Learning Objectives:- Outline gene therapy with regards to vectors and ex vivo manipulation using sickle cell disease, beta-thalassemia and active cerebral adrenoleukodystrophy as examples.
- Discuss challenges in mobilization and collection of HPCs in patients with genetic diseases and highlight the importance of a multidisciplinary approach.
- Describe various strategies for optimization of mobilization and collection of HPCs and in developing protocols and procedures to ensure success.
Moderator(s):
- Joseph (Yossi) Schwartz, MD, MPH, Director, Transfusion Services, Moffitt Cancer Center
Speaker(s):
- Reuben Jacob, MD, Medical Director Apheresis Service and Associate Director Transfusion Medicine/Blood Bank, Department of Pathology and Laboratory Medicine, Children's Healthcare of Atlanta, Assistant Professor, Department of Pediatrics, Emory University School of Medicine
- John Manis, MD, Chief, Transfusion Medicine Service, Boston Children's Hospital
Disclosures
- Reuben Jacob, MD:
No financial relationships to disclose
- John Manis, MD:
No relevant disclosure to display
- Joseph (Yossi) Schwartz, MD, MPH:
No financial relationships to disclose
AM23-ST-02-O: Effects of Blood Donor Social Behaviors on the Quality and Efficacy of Red Blood Cell Transfusions (Enduring)
Oct 18, 2023 4:00pm ‐ Oct 18, 2023 5:00pm
Expiration Date: Dec 31, 2025
Identification: AM23-ST-02-O
Credits: None available.
Red blood cell (RBC) storage is a logistic necessity. However, storage is accompanied by progressive accumulation of morphological and biochemical RBC alterations, which may ultimately impact the quality of the blood product and transfusion efficacy. The progression and severity of the storage lesion are impacted by multifactorial processes, including processing, storage additives and donor biology. Understanding how blood donor, component manufacturing, and recipient characteristics interface to impact patient outcomes is highly interesting in transfusion medicine. Accumulating molecular and clinical evidence suggests a potential impact of donor factors such as sex, age, ethnicity, and genetic variants on stored RBCs' metabolic and hemolytic properties. We will thus discuss recent clinical and molecular evidence on the impact of donors’ social behaviors (e.g., smoking, moderate alcohol consumption, diet, and exercise) on the quality of donated components and outcomes in transfusion recipients. We will review the importance of well-designed pilot studies in evaluating blood donor social behaviors, including ancillary laboratory methods to confirm donor questionnaire responses. The role of confirmatory studies utilizing big data (large databases that link donors to components and recipients) will be explored to emphasize the importance of a multivariable approach in studying recipient transfusion outcomes. Lastly, we will explore how the metabolic age of blood components is influenced by donor social behaviors, as gleaned by high throughput omics technologies. We will show how Omics approaches can directly quantify metabolic markers of nicotine, alcohol, caffeine, drug (prescription/off-the-counter), or other dietary/xenometabolite exposure and relate these measurements to the progression and severity of the storage lesion.
Learning Objectives:- Analyze how high throughput Omics technologies can be applied to enhance our understanding of the effects of blood donors’ social behaviors on the metabolic age of stored red blood cells.
- Recognize the critical importance of multivariable analyses of large linked donor-component-recipient databases in understanding the clinical impact of blood donor biology and exposures on red blood cell transfusion.
- Examine the role of pilot studies in investigating how blood donors’ social behaviors may impact red blood cell component quality and recipient transfusion outcomes.
Moderator(s):
- Robert DeSimone, MD, Director of Transfusion Medicine, Weill Cornell Medicine
Speaker(s):
- Angelo D’Alessandro, PhD, Professor, University of Colorado Anschutz Medical Campus
- Nareg Roubinian, MD, Associate Professor, University of California San Francisco
Disclosures
- Angelo D’Alessandro, PhD:
Hemanext: Consultant/Advisory Board (Ongoing); Macopharma: Consultant/Advisory Board (Ongoing); Omix Technologies Inc: Full-time/Part-time Employee or Owner (Ongoing)
- Robert DeSimone, MD:
No financial relationships to disclose
- Nareg Roubinian, MD:
No financial relationships to disclose
AM23-ST-04-O: THOR/AABB: Prehospital Transfusion: The Latest Evidence and Expert Discussion (Enduring)
Oct 18, 2023 4:00pm ‐ Oct 18, 2023 5:00pm
Expiration Date: Dec 31, 2025
Identification: AM23-ST-04-O
Credits: None available.
Prehospital transfusion is becoming a common event in the USA and around the world. There are many factors to consider when implementing such a program, like which products should be transfused and when? Which emergency vehicles should carry these products? When should prehospital patients be transfused? How can these transfusions be monitored for adverse events both during and after the transfusion? What are the regulations concerning prehospital transfusion, and who will pay for it? This session will present the latest evidence and expert opinion from leaders in trauma resuscitation on these questions and more.
Learning Objectives:- Understand the medical and regulatory fundamentals of implementing a prehospital transfusion program
- Evaluate the evidence for the use of blood products prehospital and selecting the RhD type of these products
- Appreciate nature of trauma in pediatric patients and how it differs from adults
Moderator(s):
- Luiz Amorim, MD, General Director, Hemorio
- Denese Marks, PhD, Research Program Leader, Australian Red Cross Lifeblood
Speaker(s):
- Andre Cap, MD
- Melissa Cushing, MD, Executive Vice Chair, Weill Cornell Medicine Department of Pathology and Laboratory Medicine
- Nancy Dunbar, MD, Medical Director, Blood Bank, Dartmouth-Hitchcock Medical Center
- John Holcomb, MD, Professor of Surgery, University of Alabama at Birmingham
- Robert Russell, MD, MPH, Associate Professor of Surgery, University of Alabama at Birmingham, Children's of Alabama
- Molly Sherwood, Director of Research, Allo Hope Foundation
- Phillip Spinella, MD, Professor of Surgery and Critical Care Medicine, University of Pittsburgh
- Bethany Weathersby, MEd, Executive Director, The Allo Hope Foundation
- CJ Winckler, MD, Associate Professor UT Health San Antonio / EMS Medical Director, UT Health San Antonio
- Mark Yazer, MD, Professor of Pathology, Department of Pathology, University of Pittsburgh
- Pampee Young, MD, PhD, Chief Medical Officer, American Red Cross
Disclosures
- Luiz Amorim, MD:
No financial relationships to disclose
- Andre Cap, MD:
- Melissa Cushing, MD:
Cerus: Consultant/Advisory Board (Ongoing); CSL: Consultant/Advisory Board (Ongoing); Haemonetics: Consultant/Advisory Board (Ongoing); Octapharma: Consultant/Advisory Board (Ongoing)
- Nancy Dunbar, MD:
No financial relationships to disclose
- John Holcomb, MD:
Aspen Medical: Consultant/Advisory Board (Ongoing); BARDA: Consultant/Advisory Board (Ongoing); CCJ Medical: Full-time/Part-time Employee or Owner (Ongoing); decisio health: Full-time/Part-time Employee or Owner (Ongoing); Hemostatics: Consultant/Advisory Board (Ongoing); Oxyband: Consultant/Advisory Board (Ongoing); QinFlow: Consultant/Advisory Board (Ongoing); WFIRM: Consultant/Advisory Board (Ongoing); Zibrio: Consultant/Advisory Board (Ongoing)
- Denese Marks, PhD:
Vitrafy Life Sciences: Consultant/Advisory Board (Ongoing)
- Robert Russell, MD, MPH:
No financial relationships to disclose
- Molly Sherwood:
Janssen Pharmaceuticals: Grant/Research Support (Ongoing)
- Phillip Spinella, MD:
Cerus: Consultant/Advisory Board (Ongoing); Haima: Consultant/Advisory Board (Ongoing); Hemanext: Consultant/Advisory Board (Ongoing); Kalocyte: Stock Shareholder (self-managed) (Ongoing); Octapharma: Consultant/Advisory Board (Ongoing)
- Bethany Weathersby, MEd:
No financial relationships to disclose
- CJ Winckler, MD:
No financial relationships to disclose
- Mark Yazer, MD:
grifols: Honoraria (Ongoing), Speaker's Bureau (Ongoing); Hemanext: Consultant/Advisory Board (Ongoing); Terumo: Honoraria (Ongoing), Speaker's Bureau (Ongoing)
- Pampee Young, MD, PhD:
Cerus Co: Honoraria (Ongoing); Eluciderm: Consultant/Advisory Board (Ongoing), Full-time/Part-time Employee or Owner (Ongoing); Fresenius: Consultant/Advisory Board (Ongoing)
AM23-ST-05-O: 2023 AABB RBC Transfusion Guidelines Debate: Which Restrictive Hemoglobin Threshold? (Enduring)
Oct 18, 2023 4:00pm ‐ Oct 18, 2023 5:00pm
Expiration Date: Dec 31, 2025
Identification: AM23-ST-05-O
Credits: None available.
Numerous randomized control trials compared hemoglobin concentrations to determine the optimal threshold to make transfusion decisions. Most frequently, these studies included patients requiring hip or cardiac surgery and patients admitted to intensive care units. Consistently across studies and clinical settings, restrictive transfusion thresholds have demonstrated similar outcomes compared to liberal thresholds. However, studies defined the restrictive arm using hemoglobin concentrations with ranges from 7 to 8 g/dL, depending on the setting and clinical studies. The question remains whether differences in hemoglobin concentrations (i.e., 7 versus 7.5 versus 8 g/dL) are clinically relevant. The two speakers will debate these two perspectives providing arguments for and against these options. These issues were extensively discussed within an international panel for an updated AABB-sponsored red blood cell guidelines, and the final recommendations will be presented. This session will present the new guidelines, including new recommendations for pediatric patients and patients with hematologic conditions. It will expand on some unanswered questions, such as the definition of a restrictive threshold and traumatic brain injury.
Learning Objectives:- Recognize new evidence evaluating red blood cell transfusion thresholds for transfusion
- Evaluate the clinical relevance of using a common restrictive red blood cell transfusion threshold for different clinical scenarios
- Apply this information to inform red blood cell transfusion practices
Moderator(s):
- Monica B. Pagano, MD, Division Head of Transfusion Medicine, Medical Director Transfusion Services, University of Washington
Speaker(s):
- Jeffrey Carson, MD, Provost and Distinguished Professor of Medicine, Rutgers Robert Wood Johnson Medical School
- Simon Stanworth, FRCP FRCPath DPhil, Professor of Haematology and Transfusion Medicine; Consultant Haematologist, University Oxford
Disclosures
- Jeffrey Carson, MD:
Cerus: Serve as Chair of DSMB for one of their trials (Ongoing)
- Monica Pagano, MD:
No financial relationships to disclose
- Simon Stanworth, FRCP FRCPath DPhil:
No financial relationships to disclose
AM23-ST-06-O: Deciphering the Clinical Clues: Updates to Protocols and Procedures for Anti-CD47 Agents in Clinical Laboratories (Enduring)
Oct 18, 2023 4:00pm ‐ Oct 18, 2023 5:00pm
Expiration Date: Dec 31, 2025
Identification: AM23-ST-06-O
Credits: None available.
This program has been supported by an independent educational grant from Gilead Sciences, Inc.
In anticipation of new anti-CD47 therapies in practice, clinical laboratory and blood bank personnel ¾ including pathologists, phlebotomists, nurses, and collections managers ¾ need to prepare for strategies that address the effects of anti-CD47 mAb therapy on RBCs, compatibility testing, and transfusion requirements. Please join a panel of experts in hematology, transfusion medicine, and blood banking for a live, interactive symposium at the AABB 2023 Annual Meeting in Nashville, TN. This fun and engaging event will include “escape room” challenges, as participants compete to apply key concepts presented by the faculty to virtual clinical and laboratory-based simulations. Don’t miss this unique opportunity to stay ahead of the curve in learning about the clinical and blood management implications of anti-CD47 therapy. Perhaps you’ll see your name atop the leaderboard!
Learning Objectives:- Evaluate the impact of anti-CD47 agents on blood compatibility testing
- Develop detailed laboratory protocols and procedures to facilitate timely transfusion support for patients taking anti-CD47 agents
- Utilize collaborative care strategies to ensure patients receive timely transfusions as part of supportive care
Moderator(s):
- David Sallman, MD
Speaker(s):
- Christine Lomas-Francis, MSc, FIBMS, New York Blood Center
- Lynsi Rahorst, MHPE, MLS(ASCP)SBB, Manager, Education & Training, IRL/Genomic Laboratories, New York Blood Center Enterprises
AM23-ST-07-O: Standardization of Post-Thaw Viability Testing Method for Cryopreserved Hematopoietic Progenitor Cells (Enduring)
Oct 18, 2023 4:00pm ‐ Oct 18, 2023 5:00pm
Expiration Date: Dec 31, 2025
Identification: AM23-ST-07-O
Credits: None available.
Cryopreservation preserves hematopoietic progenitor cells (HPC) for future use, but the freezing and thawing processes can impact viability. To ensure sufficient viable cells for downstream applications, post-thaw viability testing is essential. This session focuses on standardizing post-thaw viability testing methods, including thawing procedures and viability testing, with an emphasis on CAP proficiency testing and staff training.
Learning Objectives:- Explain the importance of post-thaw viability testing and the benefits of standardization in maintaining the quality of cryopreserved cell products.
- Identify optimal thawing conditions for specific cell types and implement standard thawing procedures to ensure the highest post-thaw viability.
- Select appropriate viability testing methods for specific cell types and applications, and participate in CAP proficiency testing programs to evaluate and benchmark laboratory performance, ultimately improving the quality control of cryopreserved cell products.
Moderator(s):
- Wanxing Cui, MD, PhD, CABP(H), MedStar Georgetown University Hospital
Speaker(s):
- Kevin Land, MD, CABP(H), Vice President Clinical Services, Vitalant
Disclosures
- Wanxing Cui, MD, PhD, CABP(H):
No financial relationships to disclose
- Kevin Land, MD, CABP(H):
No financial relationships to disclose
AM23-ST-08-O: Better Together: Serology and Genomics to Resolve Red Blood Cell and Platelet Antibody Cases (Enduring)
Oct 18, 2023 4:00pm ‐ Oct 18, 2023 5:00pm
Expiration Date: Dec 31, 2025
Identification: AM23-ST-08-O
Credits: None available.
Detection and identification of antibodies is critical to providing the safest and most effective red blood cell and platelet transfusions. Additionally, the resolution of typing discrepancies can be crucial to understanding alloimmunization risk in patients and is important for donors when selecting antigen negative units for transfusion. While serologic testing can identify both antibodies in plasma and antigens on red cells and platelets, in recent years, genomic testing has become an effective tool to help resolve complex serologic cases. Just as genomic testing can provide important information, serology remains vital, especially for determining alloimmunization risk in the case of novel alleles. For blood bankers and clinicians treating patients with antibodies, it is imperative to understand how serology and molecular testing complement each other to resolve the most challenging cases. In this program, we will present red cell and platelet cases, demonstrating the effective use of serologic and genomic testing.
Learning Objectives:- Describe the purpose of different serologic methods utilized in both red cell and platelet antibody cases.
- Discuss the information provided by molecular assays, including limitations of commonly used methods.
- Resolve cases of red cell and platelet antibodies utilizing a combination of both serologic and genomic testing.
Moderator(s):
- Lynsi Rahorst, MHPE, MLS(ASCP)SBB, Manager, Education & Training, IRL/Genomic Laboratories, New York Blood Center Enterprises
Speaker(s):
- Marisela G. Marchan, MSTM, MLS(ASCP)SBB, Manager, Platelet, Neutrophil Immunology Laboratory, Versiti
- Celina Montemayor Garcia, MD, PhD, Medical and Scientific Lead, Red Cell Genomics, Canadian Blood Services
Disclosures
- Marisela Marchan, MSTM, MLS(ASCP)SBB:
No financial relationships to disclose
- Celina Montemayor Garcia, MD, PhD:
International Society of Blood Transfusion: Consultant/Advisory Board (Terminated, November 30, 2021)
- Lynsi Rahorst, MHPE, MLS(ASCP)SBB:
No financial relationships to disclose
AM23-ST-09-O: Lean is the Enemy of Preparedness: Analysis of Contribution of Supply Chain Shortages Affecting Blood Supply for Transfusion Medicine (Enduring)
Oct 18, 2023 4:00pm ‐ Oct 18, 2023 5:00pm
Expiration Date: Dec 31, 2025
Identification: AM23-ST-09-O
Credits: None available.
We have experienced a record number of supply chain failures adversely affecting the national blood supply, including whole blood collection bags, apheresis collection kits, and solutions like calcium chloride. Clearly, the lack of capacity to accommodate supply chain interruptions reflects a lack of reserve inventories, which is exactly what "Lean" has driven out. Health care, unlike new car manufacturers, must always be available, and the current economic system provides a frank disincentive to having reserve supplies. Additional challenges to maintaining robust inventories include staffing and access to a more diverse donor base. Dr. John Hick, a national expert in health care preparedness, will discuss planning for a wide variety of public health challenges and stress challenges to the supply chain that we can and cannot control. He helped create a statewide system of preparedness cards at the Minnesota Department of health as part of pandemic flu planning. William (Bill) Block of BCA, a group purchasing organization, will discuss specific examples of shortages within transfusion medicine.
Learning Objectives:- Appraise the role of lean principles in precipitating the current crisis in essential components for collection, testing and processing blood components.
- Explain the role of prospective planning for various public health emergencies in having capacity to respond to supply chain challenges.
- Explore the role of federal government in creating economic incentives for blood inventories, both product and essential supplies
Moderator(s):
- Jed B. Gorlin, MD, MBA, VP and Medical Director, Memorial Blood Centers
Speaker(s):
- William Block, CEO, Blood Centers of America
- John Hick, MD, Director Emergency Preparedness, HCMC
Disclosures
- William Block:
No financial relationships to disclose
- Jed Gorlin, MD, MBA:
No financial relationships to disclose
- John Hick, MD:
No financial relationships to disclose
AM23-ST-10-O: Oral Abstract - Coagulation & Immunology (Enduring)
Oct 18, 2023 4:00pm ‐ Oct 18, 2023 5:00pm
Expiration Date: Dec 31, 2025
Identification: AM23-ST-10-O
Credits: None available.
Oral abstract session featuring the latest research on Coagulation and Immunology
Learning Objectives:- Define key pathways of RBC destruction.
- Explain how RBCs may modulate immunity.
- Recognize potential problems with diagnostics in coagulation and immunohematology.
Speaker(s):
- Magali J. Fontaine, MD PhD, Professor of Pathology and Medicine, University of Maryland School of Medicine
- Gregory Halverson, MT(ASCP)SBB,DLM, Lifesouth Community Blood Centers
- Aaron Hess, MD, PhD, University of Wisconsin
- Conrad Niebuhr, n/a, University of Virginia School of Medicine
Moderator(s):
- James Zimring, MD, PhD, BloodworksNW Research Institute
- Arijita Jash, PhD, University of Virginia
AM23-ST-11-O: Perfusion, Not Transfusion: Providing Blood Products for Organ Perfusion Before Transplantation (Enduring)
Oct 18, 2023 4:00pm ‐ Oct 18, 2023 5:00pm
Expiration Date: Dec 31, 2025
Identification: AM23-ST-11-O
Credits: None available.
Transfusion services typically issue blood to patients. Using new devices for normothermic perfusion of donor organs before transplantation presents opportunities for transfusion services to provide blood for organ perfusion rather than transfusion. These perfusion devices and techniques are poised to increase, as clinical trials have found them beneficial in increasing transplantations and reducing post-transplant complications. The process differs from routine hospital-based transfusions; the transfusion service from the transplant recipient’s hospital provides blood products to its organ procurement team, which utilizes them in organ procurement at the donor hospital and ex vivo perfusion before transplant. Accordingly, special procedures for blood product record-keeping, logistics, transportation, and billing are required. This session will review the provision of blood for organ perfusion from both transplant surgery and transfusion service perspectives.
Learning Objectives:- Describe the role of blood products in normothermic organ perfusion
- List the solid organs for which normothermic perfusion prior to transplantation has been employed
- Examine logistical and documentation requirements for transfusion services providing blood products for normothermic organ perfusion
Moderator(s):
- Elizabeth Allen, MD, Associate Professor; Associate Medical Director, University of California San Diego
Speaker(s):
- Laura Stephens, MD, Associate Professor; Associate Medical Director, University of California San Diego
- Heidi Yeh, MD, Associate Professor of Surgery; Surgical Director of Pediatric Transplant, Harvard Medical School; Massachusetts General Hospital
Disclosures
- Elizabeth Allen, MD:
No financial relationships to disclose
- Laura Stephens, MD:
Global Blood Therapeutics, Inc. (Dr. Fasano): Consultant/Advisory Board (Terminated, July 10, 2022)
- Heidi Yeh, MD:
No financial relationships to disclose